Sugi Predict

Sugi Predict / Compounds / SCHEMBL760583

SCHEMBL760583

SCHEMBL760583

COC(=O)[C@H]1C[C@H](OCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CPB1 P15086 1/20 0.46
▸ CYP2C9 P11712 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ TSHR P16473 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ EPHX2 P34913 1/20 0.44
▸ TMEM97 Q5BJF2 1/20 0.43
▸ CARM1 Q86X55 1/20 0.43
▸ PRMT6 Q96LA8 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.43
▸ PRMT8 Q9NR22 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL760582 1.00 ALDH1A1 (0.47) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL10232132 1.00 ALDH1A1 (0.47) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL21570613 0.89 CPB1 (0.53) ALDH1A1HSD17B10CPB1CYP2C9CYP2C19
SCHEMBL7261788 0.89 CPB1 (0.53) ALDH1A1HSD17B10CPB1CYP2C9CYP2C19
SCHEMBL21801247 0.87 ALDH1A1 (0.42) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL20501772 0.86 ALDH1A1 (0.52) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL15511981 0.86 ALDH1A1 (0.52) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL13470194 0.86 ALDH1A1 (0.52) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL21909387 0.85 ALDH1A1 (0.43) ALDH1A1MAPTHPGDNPSR1HSD17B10
SCHEMBL8350324 0.85 PKM (0.49) ALDH1A1MAPTNPSR1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759365-B2 Organic compounds NOVARTIS AG (CH) 2014-06-24 — — US disclosed
US-8759365-B2 Organic compounds NOVARTIS AG (CH) 2014-06-24 — — US disclosed
US-8759365-B2 Organic compounds NOVARTIS AG (CH) 2014-06-24 — — US disclosed
EP-2463282-B1 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis NOVARTIS AG (CH) 2013-08-07 — — EP disclosed
US-8440682-B2 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8440682-B2 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8440682-B2 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors NOVARTIS AG (CH) 2013-05-14 — — US disclosed
US-8420641-B2 Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives NOVARTIS AG (CH) 2013-04-16 — — US disclosed
US-8420641-B2 Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives NOVARTIS AG (CH) 2013-04-16 — — US disclosed
US-8420641-B2 Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives NOVARTIS AG (CH) 2013-04-16 — — US disclosed
US-20100311750-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-12-09 — — US disclosed
US-20100311750-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-12-09 — — US disclosed
EP-2229356-A1 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS Novartis AG (CH) 2010-09-22 — — EP disclosed
EP-2207775-A1 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS Novartis Ag (CH) 2010-07-21 — — EP disclosed
WO-2009071509-A1 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS NOVARTIS AG (CH) 2009-06-11 — — WO disclosed
WO-2009071509-A1 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS NOVARTIS AG (CH) 2009-06-11 — — WO disclosed
WO-2009059943-A1 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS NOVARTIS AG (CH) 2009-05-14 — — WO disclosed
US-20090118287-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-05-07 — — US disclosed
US-20090118287-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-05-07 — — US disclosed
US-20090118287-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118287-A1 ORGANIC COMPOUNDS CETP, NPC1, CES1 ALDH1A1 1701/4885MAPT 1522/4885HPGD 3425/4885
US-20100311750-A1 ORGANIC COMPOUNDS CETP, NPC1, CES1 ALDH1A1 1789/4885MAPT 1488/4885HPGD 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.